Search Results - "Layegh, Zohra"

Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication by Hooijberg, Femke, Layegh, Zohra, Leeuw, Maureen, Boekel, Laura, van den Berg, Stefan P H, Ruwaard, Jill, Bastida, Carla, Huitema, Alwin D R, Pel, Sara, Elkayam, Ori, de Vries, Annick, Nurmohamed, Mike, Rispens, Theo, Dorlo, Thomas P C, Wolbink, Gertjan

“…Tocilizumab in the treatment of rheumatoid arthritis (RA) is a potential candidate for concentration-guided tapering because the standard dose of tocilizumab…”
Get full text

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology by Alsoud, Dahham, Moes, Dirk Jan A R, Wang, Zhigang, Soenen, Rani, Layegh, Zohra, Barclay, Murray, Mizuno, Tomoyuki, Minichmayr, Iris K, Keizer, Ron J, Wicha, Sebastian G, Wolbink, Gertjan, Lambert, Jo, Vermeire, Séverine, de Vries, Annick, Papamichael, Konstantinos, Padullés-Zamora, Núria, Dreesen, Erwin

“…Infliximab, an anti-tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases…”
Get full text

Precision Dosing of Intravenous Tocilizumab: Development of Pharmacokinetic Model–Derived Tapering Strategies for Patients With Rheumatoid Arthritis by Hooijberg, Femke, van den Berg, Stefan P. H., Layegh, Zohra, Leeuw, Maureen, Elkayam, Ori, de Vries, Annick, Nurmohamed, Mike, Rispens, Theo, Dorlo, Thomas P. C., Wolbink, Gertjan

“…Tocilizumab targets the interleukin-6 receptor, and dosing is complex owing to its nonlinear clearance related to target binding. Therefore, tapering…”
Get full text

Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice? by Layegh, Zohra, Hooijberg, Femke, Bastida, Carla, Huitema, Alwin D R, Rispens, Theo, Wolbink, C Gertjan

Get more information

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice by Layegh, Zohra, Ruwaard, Jill, Hebing, Renske C. F., l’ Ami, Merel J., van der Weele, Wilfred, Nurmohamed, Mike T., Krieckaert, Charlotte, Wolbink, Gertjan

“…Objectives To evaluate the transition from reference infliximab Remicade to biosimilar Remsima in patients with rheumatoid arthritis (RA) or psoriatic…”
Get full text